Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

New target for Hodgkin lymphoma

Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells.

1 Aug 2007

Study looks at cancer incidence among recipients of blood from donors

Individuals who receive blood transfusions from donors with undiagnosed cancers are at no higher risk of developing malignant disease than people who receive blood from donors without cancer, according to the results of a retrospective study published in The Lancet last month.

23 Jul 2007

Blood transfusions not likely to spread cancer

23 Jul 2007

Prevention and treatment of vitamin D deficiency

Boston, MA:In a review article to appear in the July 19th issue of the New England Journal of Medicine, Dr. Michael Holick, an internationally recognized expert in vitamin D, provides an overview of his pioneering work that expounds on the important role vitamin D plays in a wide variety of chronic health conditions, as well as suggesting strategies for the prevention and treatment of vitamin D deficiency.

19 Jul 2007

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

Cancer risk in HIV, transplant patients

HIV/AIDS and kidney transplant patients are at much greater risk of contracting 20 different types of cancer than the general population, according to a land mark paper in The Lancet.

8 Jul 2007

New type of drug shows promise for chronic lymphocytic leukemia

A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

29 Jun 2007

Biovest announces interim blinded data of fast-tracked pivotal phase 3 clinical trial of BiovaxID

Biovest International announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006.

29 Jun 2007

Study finds lymphoma drug effective over long term

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.

5 Jun 2007

Adding radioimmunotherapy to chemo may help patients with lymphoma

Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.

5 Jun 2007

Heart-assist device gives Culver City man a better quality of life

Mark Heiner of Culver City reads books, paints artistically, takes walks and does laundry – activities that would be considered routine except for the fact that a four-pound disk implanted in his abdominal cavity is keeping his blood flowing.

28 May 2007

Some cancers linked to extremely low frequency electromagnetic fields

The researchers opted to study this group, because railway workers in Switzerland tend to change jobs infrequently and are exposed to much higher levels of electromagnetic field radiation than the general population.

24 May 2007

FDA approves VELCADE plus DOXIL combination for multiple myeloma

Ortho Biotech Products has announced the U.S. Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in combination with VELCADE (bortezomib) for Injection to treat patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy.

23 May 2007

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.

9 May 2007

Hepatitis C increases risk for non-Hodgkin's lymphoma

Researchers in the U.S. have found that an infection with the hepatitis C virus increases the risk of a person developing non-Hodgkin's lymphoma.

8 May 2007

Aspirin use linked to moderate drop in cancer risk

A new American Cancer Society study finds men and women who used adult-strength aspirin (325 mg or more) daily for five or more years had an approximately 15 percent lower rate of developing any cancer than those who did not use aspirin.

20 Apr 2007

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.

19 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007